November 19, 2007 – Covidien Imaging Solutions, a subsidiary of Covidien Ltd., signed a multi-year deal to supply X-ray contrast imaging agents to customers of MedAssets Supply Chain Systems, a St. Louis-based group purchasing organization, as part of Covidien's plan to broaden its distribution channels for its imaging agents.

Covidien will provide a range of products used to aid in the diagnosis of disease, including X-ray contrast agents, sodium chloride injection, USP 0.9 percent in Ultraject-prefilled syringes and MD-Gastroview (diatrizoate meglumine and diatrizoate sodium solution, USP). Covidien will also supply its full portfolio of contrast media injectors to MedAssets’ customers in accordance with a separate agreement signed earlier this year.

For more information: www.covidien.com and www.medassets.com


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now